Thanks flipper44 et. al., as you have indicated previously, this message board had talked about the RTOR program years ago. But, I think the timing was too premature for NWBio. They had not gotten to DCVax-L data-lock, and unblinding of the DCVax-L clinical trial data.
It was only after data-lock and unblinding occurred, could DCVax-L even be considered for the FDA RTOR program. NWBio would need to submit the DCVax-L TLD to the FDA to start the RTOR process. In addition, the MHRA (UK) could not fully participate in Project Orbis until after January 1, 2021.
I think the timing needed to be coordinated, and all the stars had to align.
Market Data 
Markets 
AI
